Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OCS-01
- Development stage
- Phase 3
- Lead developer
- Oculis
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
OCS-01 is a high-concentration dexamethasone ophthalmic (eye drop) formulation developed using the proprietary OPTIREACH technology by Oculis. It is designed to deliver dexamethasone efficiently from the anterior to the posterior segment of the eye via topical administration. This non-invasive approach contrasts with current therapies for diabetic macular edema (DME), which require intravitreal injections or ocular implants. The drug leverages cyclodextrin-based nanoparticles to enhance solubility and residence time on the ocular surface, enabling effective delivery to retinal tissues. Dexamethasone acts as a potent glucocorticoid receptor agonist with anti-inflammatory and immunosuppressive effects. OCS-01 is being investigated primarily for DME but also for postoperative inflammation and pain following cataract surgery, uveitic macular edema, post-surgical macular edema, retinal edema, and uveitis[1][3][4][6][7].
- Brand names
- OCS-01OCS01OCS 01
- Other names
- dexamethasone cyclodextrin nanoparticle eye dropsdexamethasone/γCD nanoparticleOPTIREACH
02
Targets
GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on OCS-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OCS-01.